Dr. Andreadis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-476-4029Fax+1 415-353-2467
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2001
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2025
PA State Medical License 2001 - 2008
NY State Medical License 2004 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia Start of enrollment: 2011 Mar 01
- Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 780 citationsATP citrate lyase inhibition can suppress tumor cell growthGeorgia Hatzivassiliou, Fangping Zhao, Daniel E. Bauer, Charalambos Andreadis, Shaw Antony N
Cancer Cell. 2005-10-01 - 396 citationsATP citrate lyase is an important component of cell growth and transformationDaniel E. Bauer, Georgia Hatzivassiliou, Fangping Zhao, Charalambos Andreadis, Craig B. Thompson
Oncogene. 2005-09-15 - 2303 citationsTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J. Schuster, Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann
The New England Journal of Medicine. 2019-01-03
Abstracts/Posters
- Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T ConsortiumCharalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Junior Faculty Career-Development Session60th American Society of Hematology Annual Meeting - 12/1/2018
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
DLBCL: Major New Treatment BreakthroughsMay 17th, 2023- What Is Non-Hodgkin’s Lymphoma?September 8th, 2022
- Clinical Edge Journal Scan Commentary: AML August 2021August 2nd, 2021
- Join now to see all
Other Languages
- Greek
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
